Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Toxicity testing in mice for PhG-alpha-1 complete
June 16th, 2005
PharmaGap Inc. (GAP) announced the formal completion of acute toxicity testing in mice for its lead cancer drug, PhG-alpha-1. Testing took place in Ottawa at accredited facilities operated by the Institute of Biological Sciences, part of the National Research Council of Canada, under the supervision of an independent veterinarian. The drug was delivered to test groups of mice by intravenous injection, orally and by direct application to the skin. PharmaGap's novel lead cancer drug, PhG-alpha-1, is designed to selectively target and inhibit the activity of Protein Kinase C alpha (PKC alpha) in cancer cells. As verified by numerous researchers...
Source: Women's Health Weekly (2005-06-16)
|
